Several analysts have recently updated their ratings and price targets for AstraZeneca (LON: AZN):
- 4/12/2023 – AstraZeneca had its “overweight” rating reaffirmed by analysts at Barclays PLC.
- 4/11/2023 – AstraZeneca was upgraded by analysts at Morgan Stanley to an “overweight” rating.
- 4/11/2023 – AstraZeneca had its price target lowered by analysts at Guggenheim from £127 ($157.28) to £119 ($147.37).
- 4/4/2023 – AstraZeneca had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a £130 ($160.99) price target on the stock.
- 3/16/2023 – AstraZeneca was given a new £124 ($153.56) price target on by analysts at Berenberg Bank.
- 3/13/2023 – AstraZeneca was given a new £130 ($160.99) price target on by analysts at Deutsche Bank Aktiengesellschaft.
- 3/10/2023 – AstraZeneca was given a new £119 ($147.37) price target on by analysts at UBS Group AG.
- 3/9/2023 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
- 3/9/2023 – AstraZeneca was given a new £135 ($167.18) price target on by analysts at JPMorgan Chase & Co..
- 3/7/2023 – AstraZeneca had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a £130 ($160.99) price target on the stock.
- 3/2/2023 – AstraZeneca was given a new £135 ($167.18) price target on by analysts at JPMorgan Chase & Co..
- 2/21/2023 – AstraZeneca was given a new £119 ($147.37) price target on by analysts at UBS Group AG.
- 2/13/2023 – AstraZeneca was given a new £130 ($160.99) price target on by analysts at Deutsche Bank Aktiengesellschaft.
AstraZeneca Stock Performance
Shares of LON AZN opened at £118.22 ($146.40) on Thursday. The stock has a 50 day moving average price of £110.69 and a 200 day moving average price of £108.86. AstraZeneca PLC has a 52 week low of GBX 9,399 ($116.40) and a 52 week high of £128.28 ($158.87). The company has a debt-to-equity ratio of 84.02, a quick ratio of 0.59 and a current ratio of 0.86. The stock has a market capitalization of £183.24 billion, a PE ratio of 6,954.12, a price-to-earnings-growth ratio of 2.25 and a beta of 0.17.
AstraZeneca Increases Dividend
The firm also recently disclosed a dividend, which was paid on Monday, March 27th. Shareholders of record on Thursday, February 23rd were paid a GBX 162.80 ($2.02) dividend. This is a positive change from AstraZeneca’s previous dividend of $76.40. The ex-dividend date of this dividend was Thursday, February 23rd. This represents a yield of 1.51%. AstraZeneca’s dividend payout ratio is currently 14,058.82%.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Recommended Stories
- Should Cheesecake Factory Stock Be On Your Menu?
- Buffett Reduces Taiwan Semiconductor Stake After This Happened
- Don’t Get Bullish On The S&P 500 Because Of The CPI Report
- Shockwave Medical Gets 10% Jolt, Leads Medical Gear Makers Higher
- Proterra Inc., A Penny Stock To Put On The Watchlist
Receive News & Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.
